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Abstract 
We summarise recent emerging evidence around tuberculosis (TB) 
transmission and its role in tuberculosis epidemiology, and in novel TB 
screening and diagnostic tests that will likely become available in low-
resource settings in the near future. Little consideration has been paid 
to how these novel new tests will be implemented, nor what the 
consequences for individuals, communities and health systems will 
be. In particular, because of low specificity and consequent false-
positive diagnoses, and the low percentage of people who “screen 
positive” that will go onto develop active pulmonary disease, there is 
significant potential for inappropriate initiation of TB treatment, as 
well as stigmatisation, loss of livelihoods and in some setting 
institutionalisation, with uncertain benefit for individual health or 
community transmission. 
We use analogy to prompt consideration of how and where new TB 
screening tests could be implemented in TB screening programmes in 
low-resource settings. Acceptance and confidence in TB screening 
programmes depends on well-functioning public health programmes 
that use screening algorithms that minimise harms and balance 
population benefits with autonomy and respect for individuals. Before 
new TB screening tests and algorithms are introduced, more evidence 
for their effectiveness, costs, benefits and harms under real-world 
conditions are required.
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singing represents the indolent transition from latent to active 
TB. A number of internal and external factors will influence 
the speed and likelihood of the kettle boiling and generating 
enough steam to make the kettle sing, and steam (representing 
infectiousness) can still be omitted prior to this. If we want to 
intervene to reduce transmission, sickness and death before the 
kettle begins to boil, we need better approaches to detect 
this than just a whistle.
New TB screening tests at various stages of development 
and implementation that have potential to identify people 
with indolent disease with no or minimal symptoms—as well 
as in symptomatic people—include: automated chest x-ray 
interpretation using software algorithms, C-reactive protein, 
and face-mask sampling with Xpert testing of respiratory drop-
lets captured by a sampling matrix integrated in masks. Host 
response assays (measuring abundance of transcripts or immune 
responses associated with TB disease) may additionally be used 
to predict which people will progress to clinical disease in the 
future, potentially with greater accuracy than existing tuberculin 
skin test and interferon gamma response assay tests8. Importantly, 
all of these tests have been designed with careful consideration 
for implementation in low-resource settings. Field studies 
have shown that sensitivity for microbiologically-confirmed 
TB is high, and implementation is feasible and acceptable. 
However, before widespread introduction into TB screening 
programmes, careful consideration of risk-benefit trade-offs 
(both for people and health programmes) and cost-effectiveness 
are required.
To date, there is no empirical published data from randomised 
trials on the effectiveness and cost-effectiveness of these new 
screening tools for improving patient-important outcomes 
such as mortality, morbidity and quality of life, nor on their 
impact on the epidemiology of TB (population incidence, preva-
lence, mortality and transmission). Further, the large majority of 
people identified early on in the disease process without symp-
toms will likely not progress to develop clinically apparent 
disease, and it is unclear to what extent they or their communi-
ties would benefit from antituberculosis treatment. Although 
diagnostic delay with new screening tests may be shortened, spe-
cificity is suboptimal for many of them, and in settings where 
TB prevalence is low or moderate, a large fraction of posi-
tive TB screens are likely to be false-positive. Robust, 
high-specificity confirmatory testing algorithms will be 
required to minimise the harms associated with a false-positive 
screening test, including exposure to potential treatment 
toxicity, stigma and discrimination, loss of income gener-
ating activities, and in some settings institutionalisation. 
Unfortunately, in many low-resource settings, high-quality speci-
men transfer, microbiological testing systems and laboratory 
networks for confirmatory testing are not available or require 
strengthening.
Acceptance and confidence in TB screening programmes 
depends on well-functioning public health programmes that use 
screening algorithms that minimise harms and balance 
population benefits with autonomy and respect for individuals. 
Before new TB screening tests and algorithms are introduced, 
Progress  towards  achieving  the  global  End  TB  Strategy  tar-
gets  to  eliminate  tuberculosis  (TB)  as  a  public  health  concern
by  2035  have  been  unacceptably  slow1.  The  reduction  in  the 
number  of  TB  deaths  between  2015  and  2020  was  11%,  only
one-third  of  the  35%  milestone  stipulated  in  the  End  TB  Strat-
egy.  Incidence  of  TB  fell  by  only  6%  over  this  five-year
period,  well  short  of  the  20%  target1.  The  End  TB  Strategy 
explicitly  noted  that  rapid  improvements  in  TB  burden  would
not  be  achieved  with  existing  diagnostics  and  that  new  tech-
nologies  need  to  be  developed,  evaluated  and  integrated  into
TB programmes.
Screening  for  TB—both  in  the  community  and  among  peo-
ple  attending  health  facilities—has  been  long  recommended
in  World  Health  Organization  (WHO)  guidelines,  with  the 
underlying  rationale  that  high-quality  screening  programmes
in  priority  populations  could  identify  and  treat  people  with 
infectious  TB  earlier,  improving  their  individual  health  out-
comes  and  reducing  community  transmission2.  But  the  Achilles
heel  of  TB  screening  programmes  has  been  the  screening  tools 
available;  we  are  attempting  to  eliminate  the  epidemic  in  the 
21st century  with  20th century  technologies.  However,  there
are  some  reasons  to  be  optimistic  that  an  acceleration  in
progress may be achievable.
WHO  and  national  guidelines  recommend  symptom  screen-
ing  for  TB  for  people  who  attend  health  facilities  in  high  TB 
burden  settings  to  determine  whether  sputum-based  diagnostic
tests  should  be  done2.  In  communities,  as  part  of  active  case 
finding  interventions  or  mass  screening  programmes,  the  initial
screen  is  usually  a  symptom  screen  or  chest  X-ray,  with
sputum-based  diagnostic  testing  for  those  with  TB  symptoms  or
abnormal findings on chest X-ray.
New  and  emerging  insights  into  the  natural  history  of  TB  and  a 
revitalised  pipeline  of  screening  and  diagnostic  tests  for  TB 
have  started  to  challenge  long-standing  assumptions  about  how
TB  screening  should  be  implemented,  and  rightly  place  empha-
sis  on  availability  and  feasibility  for  low-resource,  high
TB  burden  settings.  Analysis  of  TB  prevalence  survey  data3,
high-resolution  functional  scanning  of  the  lungs4,  and  careful 
study  of  adults  undergoing  facemask  sampling5 and  sampling
of  particles  aerosolised  through  speaking  and  respiration  in 
research  chambers6 has  shown  that  our  long-held  assumptions 
about  the  natural  history  of TB  emission  by  individuals  may  not 
be  true.  An  estimated  54%  of  people  with  prevalent  TB  in  the 
community  do  not  report  symptoms  when  screened3.  Instead  of
progressing  from  infection  through  a  latent  non-infectious  stage 
to  infectious  active  pulmonary  disease,  we  now  recognise  that 
people  with  immunological  or  radiological  evidence  of  prior  TB 
exposure  may  undergo  periods  of  fluctuating  disease  activity
and  infectivity7.  This  period  of  indolent  disease  is  some-
times  referred  to  as  subclinical,  minimal  or  incipient  TB.  By
way  of  analogy  imagine  the  lungs  of  someone  with  active 
TB  disease  to  be  like  a  whistling  kettle  on  an  open  fire,  when
the  kettle  sings  (presentation  with  symptomatic  disease)  rapid
intervention  occurs  to  stop  this  (investigation  and  treatment
of  TB).  The  period  between  lighting  the  fire  and  the  kettle
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more evidence for their effectiveness, costs, benefits and 
harms under real-world conditions are required.
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